Venus Remedies joins India AMR Innovation Hub
News

Venus Remedies joins India AMR Innovation Hub

lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid

  • By IPP Bureau | March 07, 2023

Stepping up its determined battle to counter the grave public health threat posed by antimicrobial resistance (AMR), Venus Remedies, one of India's leading research-driven pharmaceutical companies, has become a member of the India AMR Innovation Hub (lAIH), a collaborative platform of key national and international stakeholders dedicated to reducing the AMR burden in India, with the aim of evolving a consensus and support system for long-term solutions to this impending global health catastrophe.

A program driven by the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, India, the lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid.

Chaired by the Principal Scientific Adviser to the Government of India, the lAIH has many members from the government academia, industry, and philanthropic, and not-for-profit organisations like the World Health Organisation (WHO), Bill and Melinda Gates Foundation, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (GARB-X), Global Antibiotic Research a Development Partnership (GARDP), and the Indian Council of Medical Research (lCMR) have joined hands to develop suitable public health policies, build capacities, nurture R&D, and undertake AMR stewardship activities to counter the challenge posed by drug-resistant pathogens.

Welcoming Venus Remedies as a new lAIH member, C-CAMP CEO and Director Dr. Taslimarif Saiyed said, "We are delighted to have Venus Remedies joining lAIH. The company is a key player in the Indian antibiotics/pharma domain with a track record of responsible manufacturing and access to antibiotics, encouraging appropriate antibiotic use, antibiotic stewardship activities in the clinical domain and developing new breakthrough drugs/therapeutics. This is exactly the kind of holistic AMR viewpoint we aim to bring to lAIH to boost our collective efforts in AMR mitigation."

Describing the IAIH membership as a continuation of the company's commitment to combat AMR, Saransh Chaudhary, President - Global Critical Care, Venus Remedies Ltd. and CEO, Venus Medicine Research Centre (VMRC) said, "The collaborative efforts of national and global stakeholders under changes of the lAIH will help lndia devise sustainable solutions to AMR, shape relevant AMR policies, and bridge the gaps in antibiotic research and manufacturing with focus on access and rational use. With the lAIH going about its mission to nurture an AMR innovation ecosystem in India through interventions like developing an access and public health policy capability and capacity building, AMR stewardship and public communication, we believe that it can collectively become an anchor for effecting a systemic change in the Indian AMR research and innovation landscape."

In order to facilitate a comprehensive understanding of the incidence, causes and patterns of AMR in the country with the aim of redefining the way it is being handled, VMRC, the company's R&D wing, has set up a non-profit organisation called Preserving Life of Existing Antibiotics (PLEA) which seeks to become a rallying point in the long-winded struggle against AMR through a national surveillance programme on antibiotic resistance by bringing together scientists, researchers and clinicians across various disciplines.

"Under the aegis of PLEA, we have established a vast network of healthcare institutions and research centres across India for the surveillance of AMR through a comprehensive software system. Implemented through a network of 150 centres spanning 15 states. including leading hospitals and research institutes, for data collection, feed, and analysis. This initiative is aimed at understanding trends of emerging resistance. We have so far mapped emerging AMR patterns for more than 40 antibiotics/combinations for close to 25,000 strains, which has immensely helped physicians make informed decisions on designing therapy. We have also reached out to more than 5 lakh people, including 50,000 doctors and paramedical staff, through our awareness campaigns aimed at reducing the unwarranted use of antibiotics," said Chaudhary.

Upcoming E-conference

Other Related stories

Startup

Digitization